Ferrer Internacional
Grupo Ferrer Internacional is a privately-held European pharmaceutical company based in Barcelona, specializing in research and development across multiple sectors, including pharmaceuticals, health, fine chemicals, and food. The company commercializes its human healthcare products in over 95 countries, supported by a network of 24 international affiliates and numerous partners and distributors. Ferrer is involved in the entire pharmaceutical value chain, encompassing activities from research and development to international marketing, as well as the development and manufacturing of raw materials and finished pharmaceuticals. Its research facilities are located in Spain and Germany, while its manufacturing sites are distributed across Europe and Latin America. Ferrer's diverse product portfolio includes prescription drugs, hospital equipment, personalized medicines, vaccines, and consumer healthcare products.
ABAC Therapeutics
Series A in 2018
ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents aimed at treating multidrug-resistant (MDR) Gram-negative infections. Established in 2014, the company utilizes its innovative PasNas drug discovery platform to identify pathogen-specific antibacterial properties of various molecules. This platform not only focuses on potent antibacterial activity but also emphasizes the importance of favorable pharmacokinetics and toxicological profiles to enhance the likelihood of success in clinical development. ABAC Therapeutics seeks to provide first-in-class therapeutic alternatives for patients suffering from infections caused by antibiotic-resistant bacterial pathogens, particularly targeting the significant challenge posed by the major MDR Gram-negative bacteria. As of November 2019, the company operates as a subsidiary of Tibidabo Ventures.
Alexza Pharmaceuticals
Acquisition in 2016
Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.
Venter Pharma
Venture Round in 2014
Venter Pharma SL is a biotech company based in Alcobendas, Spain, specializing in the development of diagnostic drugs for lactose intolerance and other digestive disorders. Founded in 2003, the company emerged from research conducted by PhD. Juan José Aragón Reyes and Alfonso Fernández Mayoralas at the Autonomous University of Madrid and the Spanish National Research Council. Venter Pharma focuses on creating innovative solutions for high-prevalence digestive pathologies, particularly lactose intolerance and inflammatory illnesses. Its flagship product, LacTEST®, utilizes a novel active substance called Gaxilose to facilitate accurate diagnosis, aiming to simplify and enhance the effectiveness of clinical evaluations. Through its efforts, Venter Pharma seeks to provide patients with advanced treatment options that promote faster recovery.
Oryzon Genomics
Funding Round in 2006
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.